FDA Q1 2025 New Drug Approvals

Posted: 2025-04-14 19:39:40 UTC

@Nature Reviews Drug DiscoveryNatRevDrugDisc

#BreastCancer

#PainManagement

#FDA

#Q12025

#NewDrugs

#Suzetigrine

#DatopotamabDeruxtecan

Read With Caution

This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.

Full Thread

This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.

Read With Caution

Verification Details

Status

In Progress

VerifiedPartially VerifiedFalse

Last Updated

2025-04-14 19:39:59 UTC

Verified By

Rollup News

TL;DR;

In Q1 2025, the FDA approved only 7 new drugs, including two potential blockbusters: suzetigrine for pain and datopotamab deruxtecan for breast cancer.

Key Impact Areas

FDA new drug approvals

Suzetigrine for pain

Datopotamab deruxtecan for breast cancer

Potential blockbuster drugs

Challenges

Only 7 new drugs approved in Q1

FDA Q1 2025 New Drug Approvals

Read With Caution

Full Thread

Read With Caution

Verification Details

TL;DR;

Key Impact Areas

Challenges

Claims

Deliberation Map

Similar Rollups